肾功能正常者使用临床批准剂量钆基对比剂后的皮肤毒性:临床前与临床研究现状
该综述检索2000年至2022年文献,纳入40项分析肾功能正常(eGFR>30 mL/min/1.73m²)且使用0.1 mmol/kg钆基对比剂(GBCA)的临床前与临床研究,发现线性GBCA比大环类更易在皮肤沉积但随时间减少且无组织学改变,目前无证据支持临床剂量GBCA与皮肤表现存在因果关系。
要点
- 线性GBCA在肾功能正常者皮肤中沉积浓度高于大环类,但沉积随时间减少且无宏观或组织学改变。
- 临床前体外研究提示钆可激活真皮成纤维细胞并促纤维化反应。
- 目前无 conclusive 证据支持临床剂量GBCA与皮肤表现存在因果关系。
核心结论
- 钆可在皮肤产生促纤维化反应,尤其作用于成纤维细胞;线性GBCA在肾功能正常者皮肤中沉积浓度更高,但至今无证据证明临床剂量GBCA与皮肤后果存在因果关系,对偶发皮肤表现者应考虑多种未明因素。
研究设计与样本
- 综述,检索MEDLINE和PubMed 2000年1月至2022年12月文献,纳入40项研究:体外研究分析人真皮成纤维细胞对钆化合物的反应;动物和临床研究仅纳入肾功能保留(eGFR>30 mL/min/1.73m²)且使用与常用剂量相似(0.1 mmol/kg)GBCA者。
关键影像表现/征象
- 临床前体外研究提示钆化合物可通过激活和增殖真皮成纤维细胞并促进其肌成纤维细胞分化,在皮肤产生促纤维化反应。
- 钆通过增加基质金属蛋白酶-1和金属蛋白酶组织抑制剂-1水平影响胶原产生过程和皮肤胶原含量。
- 临床前动物研究表明线性GBCA应用时钆以更高浓度沉积于皮肤,但这些沉积随时间减少且无明显的宏观或组织学改变。
- 临床研究显示肾功能正常者静脉注射线性GBCA后皮肤和毛发中可检出钆且浓度高于大环类GBCA,但沉积随时间减少且无皮肤或组织学改变。
- 与线性GBCA暴露相关的亚临床真皮受累可能在脑MRI上可检出。
临床应用与阅片要点
- 作者指出,对于肾功能正常且皮肤临床表现与GBCA给药时间相关的偶发患者,应考虑多种尚待确定的因素。
- GBCA诱导小纤维神经病的临床相关性仍有待确定。
局限性
- GBCA诱导小纤维神经病的临床相关性仍有待确定。
- 多种因素尚待确定,应予以考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to summarize the current preclinical and clinical evidence on the association between exposure to gadolinium (Gd) compounds and skin toxicity in a setting similar to clinical practice.
MATERIALS AND METHODS: A search of MEDLINE and PubMed references from January 2000 to December 2022 was performed using keywords related to gadolinium deposition and its effects on the skin, such as "gadolinium," "gadolinium-based contrast agents," "skin," "deposition," and "toxicity." In addition, cross-referencing was added when appropriate. For preclinical in vitro studies, we included all the studies that analyzed the response of human dermal fibroblasts to exposure to various gadolinium compounds. For preclinical animal studies and clinical studies, we included only those that analyzed animals or patients with preserved renal function (estimated glomerular filtration rate >30 mL/min/1.73 m 2 ), using a dosage of gadolinium-based contrast agents (GBCAs) similar to that commonly applied (0.1 mmol/kg).
RESULTS: Forty studies were selected. Preclinical findings suggest that Gd compounds can produce profibrotic responses in the skin in vitro, through the activation and proliferation of dermal fibroblasts and promoting their myofibroblast differentiation. Gadolinium influences the process of collagen production and the collagen content of skin, by increasing the levels of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1. Preclinical animal studies show that Gd can deposit in the skin with higher concentrations when linear GBCAs are applied. However, these deposits decrease over time and are not associated with obvious macroscopic or histological modifications. The clinical relevance of GBCAs in inducing small fiber neuropathy remains to be determined. Clinical studies show that Gd is detectable in the skin and hair of subjects with normal renal function in higher concentrations after intravenous administration of linear compared with macrocyclic GBCA. However, these deposits decrease over time and are not associated with cutaneous or histological modifications. Also, subclinical dermal involvement related to linear GBCA exposure may be detectable on brain MRI. There is no conclusive evidence to support a causal relationship between GBCA administration at the clinical dose and cutaneous manifestations in patients with normal renal function.
CONCLUSIONS: Gadolinium can produce profibrotic responses in the skin, especially acting on fibroblasts, as shown by preclinical in vitro studies. Gadolinium deposits are detectable in the skin even in subjects with normal renal function with higher concentrations when linear GBCAs are used, as confirmed by both preclinical animal and human studies. There is no proof to date of a cause-effect relationship between GBCA administration at clinical doses and cutaneous consequences in patients with normal renal function. Multiple factors, yet to be determined, should be considered for sporadic patients with normal renal function who develop clinical skin manifestations temporally related to GBCA administration.
引用
- Parillo M, Mallio CA, Van der Molen AJ, et al. Skin Toxicity After Exposure to Gadolinium-Based Contrast Agents in Normal Renal Function, Using Clinical Approved Doses: Current Status of Preclinical and Clinical Studies. Invest Radiol. 2023. PMID: 37185158. doi:10.1097/RLI.0000000000000973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。